Evaluation of antileishmanial potential of the antidepressant escitalopram in Leishmania infantum

Autor(es)

Lima, Marta Lopes ^[1] ; Amaral, Maiara ^{[2, 3]} ; Treiger Borborema, Samanta Etel ^[2] ; Tempone, Andre Gustavo ^[2]

Afiliação do(s) autor(es)

^[1] Univ Dundee, Wellcome Ctr Antiinfect Res, Sch Life Sci, Div Biol Chem & Drug Discovery, Dundee DD1 5EH - Scotland

^[2] Adolfo Lutz Inst, Ctr Parasitol & Mycol, BR-01246000 Sao Paulo - Brazil

^[3] Univ Sao Paulo, Fac Med, Inst Med Trop, BR-05403000 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Journal of Pharmaceutical and Biomedical Analysis; v. 209, FEB 5 2022.
• Citações Web of Science: 0

Resumo

Neglected tropical diseases (NTDs) such as visceral leishmaniasis (VL) present a limited and toxic therapeutic arsenal, and drug repositioning represents a safe and cost-effective approach. In this work, we investigated the antileishmanial potential and the mechanism of lethal action of the antidepressant escitalopram. The efficacy of escitalopram was determined ex-vivo using the intracellular Leishmania (L.) infantum amastigote model and the mammalian cytotoxicity was determined by the colorimetric MTT assay. The cellular and molecular alterations induced by the drug were investigated using spectrofluorimetry, a luminescence assay and flow cytometry. Our data revealed that escitalopram was active and selective against L. infantum parasites, with an IC50 value of 25 mu M and a 50% cytotoxic concentration (CC50) of 184 mu M. By using the fluorescent probes SYTOX (R) Green and DiSBAC(2)(3), the drug showed no alterations in the plasma membrane permeability nor in the electric potential of the membrane (Delta psi(p)); however, after a short-time incubation, the drug caused a dose-dependent up-regulation of the calcium levels, leading to the depolarization of the mitochondrial membrane potential Delta psi(m)) and a reduction of the ATP levels. No up regulation of reactive oxygen (ROS) was observed. In the cell cycle analysis, escitalopram induced a dose dependent increase of the parasites at the sub G(0)/G(1) stage, representing fragmented DNA. Escitalopram presented a selective antileishmanial activity, with disruption of single mitochondrion and interference in the cell cycle. Approved drugs such as escitalopram may represent a promising approach for NTDs and can be considered in future animal efficacy studies. (C) 2021 Elsevier B.V. All rights reserved. (AU)

• Processo FAPESP: 19/10434-4 - Marcadores celulares e moleculares de resposta terapêutica de fármacos anti-histamínicos no tratamento da Leishmaniose visceral
• Beneficiário: Samanta Etel Treiger Borborema de Carvalho
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 17/50333-7 - Plano de desenvolvimento institucional em pesquisa do Instituto Adolfo Lutz (PDIp)
• Beneficiário: Carlos Henrique Camargo
• Modalidade de apoio: Auxílio à Pesquisa - Programa Modernização de Institutos Estaduais de Pesquisa